Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + bicalutamide + docetaxel + LHRH agonist
- Development stage
- Unknown
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous, Intramuscular
01
Overview
This regimen is a multimodality systemic therapy evaluated in a Phase II clinical trial (NCT00658697) led by the Dana-Farber Cancer Institute for the treatment of men with biochemical recurrence of prostate cancer. The combination consists of the chemotherapy agent docetaxel, the anti-VEGF monoclonal antibody bevacizumab (Avastin), and androgen deprivation therapy (ADT). The ADT component specifically involves a luteinizing hormone-releasing hormone (LHRH) agonist and the androgen receptor antagonist bicalutamide. The treatment is designed to target rising PSA levels in patients who have previously undergone surgery or radiation but show no evidence of metastatic disease, aiming to delay or prevent the progression to metastatic castration-resistant prostate cancer.
- Other names
- ADT-Dana-Farber Cancer Institute-prostate cancerAvastin, Docetaxel and Androgen Deprivation TherapyNCT00658697 regimenNCT-00658697 regimenNCT 00658697 regimen
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)VEGFA (Vascular endothelial growth factor A)AR (Adrenergic receptors)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bevacizumab + bicalutamide + docetaxel + LHRH agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + bicalutamide + docetaxel + LHRH agonist.